Quantcast
Last updated on April 19, 2014 at 18:42 EDT

GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences

March 26, 2013

At Biovision Investor Conference and IN Medical Device 360 Dublin, GlySure will disclose cardiac surgery ICU trial findings and progress toward CE mark

OXFORD, England, March 26, 2013 /PRNewswire/ –

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM)
systems, will present the results of its cardiac surgery intensive care trial and plans
for CE mark testing at two leading MedTech conferences this spring. GlySure CEO
Christopher Jones will speak at the inaugural Biovision Investor Conference on March 26th,
2013 in Lyon, France, and at the Investment In Innovation (INcubed) Medical Device
360degree(s) Conference on April 17th, 2013 in Dublin, Ireland.

Studies have shown that inadequate post-operative blood sugar control in heart surgery
patients is associated with an increased risk of major complications and death. GlySure
recently completed a trial of its CBGM system on cardiac surgery patients. The study
revealed GlySure’s technology can be used to continuously measure glucose levels with an
extremely high degree of accuracy and repeatability across two-to-five days of a patient’s
stay in ICU, which is key to effectively implementing TGC.

At the Biovision Investor Conference and INcubed Medical Device 360degree(s)
Conference, Jones will share results of GlySure’s cardiac surgery ICU trial and outline
the company’s plans for CE regulatory trials, which are set to commence this Spring.

Biovision has selected GlySure as one of 35 life science companies to present to its
forum of international capital investors and large healthcare companies seeking
partnerships and innovation, while the producers of the (INcubed) Medical Device
360degree(s) Conference have chosen GlySure as one of 35 early stage companies to appear
before its global audience of VCs, top investors and corporate acquirers.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a
proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for
implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).
The company has demonstrated through ICU testing highly accurate sensors, which can
provide continuous glucose readings throughout the length of a patient’s stay in the ICU.
GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20
employees. The company’s products are not approved for use in the U.S. or Europe.

http://www.glysure.com

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127.
kara@kdvcommunications.com

SOURCE GlySure


Source: PR Newswire